Literature DB >> 33495710

A contemporary insight of metabolomics approach for COVID-19: Potential for novel therapeutic and diagnostic targets.

Mohammad Asim1, Brijesh Sathian2,3, Indrajit Banerjee4, Jared Robinson4.   

Abstract

The Coronavirus disease 2019 (COVID-19) pandemic is caused by rapidly spreading pathogenic virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that affects vast majority of population worldwide. Although, around 80% of the cases had mild infection but still remaining 20% had developed respiratory failure and dysfunction of other organs that necessitate urgent oxygen therapy or specific interventions. Therefore, it is imperative to establish novel prognostic approaches to screen patients at high-risk of developing severe complications. The primary focus of current research for COVID-19 is to discover safe and efficacious vaccine for prevention and effective treatment for better management of the patients to overcome the pandemic. To achieve this goal, it is imperative to have better understanding of the molecular pathways involved in the pathophysiology and progression of severe COVID-19. The surge for reliable diagnostics and therapeutics targets for COVID-19 highlighted the great potential of high-throughput approach like metabolomics which may enable the development of personalized medicine.
© 2020 CEA& INEA.

Entities:  

Keywords:  COVID-19; diagnosis; metabolomics; severe disease; therapeutic targets

Year:  2020        PMID: 33495710      PMCID: PMC7812325          DOI: 10.3126/nje.v10i4.33964

Source DB:  PubMed          Journal:  Nepal J Epidemiol


  5 in total

1.  1H qNMR-Based Metabolomics Discrimination of Covid-19 Severity.

Authors:  Banny S B Correia; Vinicius G Ferreira; Priscila M F D Piagge; Mariana B Almeida; Nilson A Assunção; Joyce R S Raimundo; Fernando L A Fonseca; Emanuel Carrilho; Daniel R Cardoso
Journal:  J Proteome Res       Date:  2022-06-08       Impact factor: 5.370

2.  COVID-19: Are reinfections a global health threat?

Authors:  Indrajit Banerjee; Jared Robinson; Brijesh Sathian
Journal:  Nepal J Epidemiol       Date:  2021-03-31

3.  Metabolite profile of COVID-19 revealed by UPLC-MS/MS-based widely targeted metabolomics.

Authors:  Jun Liu; Zhi-Bin Li; Qi-Qi Lu; Yi Yu; Shan-Qiang Zhang; Pei-Feng Ke; Fan Zhang; Ji-Cheng Li
Journal:  Front Immunol       Date:  2022-07-18       Impact factor: 8.786

4.  Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19.

Authors:  Yamilé López-Hernández; Joel Monárrez-Espino; Ana-Sofía Herrera-van Oostdam; Julio Enrique Castañeda Delgado; Lun Zhang; Jiamin Zheng; Juan José Oropeza Valdez; Rupasri Mandal; Fátima de Lourdes Ochoa González; Juan Carlos Borrego Moreno; Flor M Trejo-Medinilla; Jesús Adrián López; José Antonio Enciso Moreno; David S Wishart
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

5.  Integration Analysis of Pharmacokinetics and Metabolomics to Predict Metabolic Phenotype and Drug Exposure of Remdesivir.

Authors:  Ping Du; Guoyong Wang; Ting Hu; Han Li; Zhuoling An
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.